Latest news with #medRxiv
The Sun
09-07-2025
- Health
- The Sun
The popular nighttime habit that could be raising your risk of killer heart disease – and 3 other things to avoid
DO YOU fall asleep with the TV on or use a night light? Being exposed to light during the night can up your risk of heart disease, scientists say. 1 The brighter the light, the higher the risk of five cardiovascular diseases, a study from the Flinders Health and Medical Research Institute suggested. "Light at night causes circadian disruption, which is a known risk factor for adverse cardiovascular outcomes," researchers wrote in medRxiv. Circadian rhythms - the body's 24-hour clock that governs when we feel sleepy or alert as well as other biological functions - play a role in regulating blood pressure, clot formation and heart rate. Even short-term circadian disruption has been linked to increased risk of blood clots, elevated heart rate and blood pressure and inflammation, study authors wrote. For instance, studies show that shift workers exposed to light at night have a higher risk of "adverse cardiovascular events, coronary heart disease, heart failure, atrial fibrillation, and mortality". Exposure to light at nighttime can also come from electronic devices like phones, laptops and TV, lights within the home or streetlights outside. Scientists noted that previous studies into the subject relied on smaller pools of participants and subjective reports on light exposure. Their study of 88,905 people - which has yet to be peer reviewed - used data captured from wrist-worn light sensors and had a follow-up period of nine and a half years. It assessed whether exposure to light at night was linked to a higher risk of coronary artery disease, heart attack, heart failure, atrial fibrillation, and stroke. The data was used to create "24-hour light exposure profiles for each participant". I spent three days at a sleep retreat - these are the top 7 things I learnt Researchers then compared this to records from hospital admissions, primary care, self-reports, and death register reports. Participants hadn't been diagnosed with any form of cardiovascular disease at the start of the study. Study authors found: "Individuals exposed to higher levels of personal night light had higher risks for incident coronary artery disease, heart attack, heart failure, atrial fibrillation, and stroke. "These findings support night light exposure as an important risk factor for adverse cardiovascular health. "Exposure to night light predicted higher risk of cardiovascular diseases, with clear dose-dependent relationships for each outcome," they added. This meant that the brighter the light, the higher participants' risk of disease. Those exposed to the brightest lights at night had a 23-32 per cent higher risk of coronary artery disease, a 45-56 per cent higher risk of heart attack, and a 28-30 per cent higher risk of stroke. They also had a 45-56 per cent higher risk of heart failure, and a 28-32 per cent higher risk of atrial fibrillation. How to reduce your risk of heart attacks and stroke You can reduce your risk of heart attack and stroke with many of the same methods. Heart attacks and strokes, although affecting different organs of the body, are both what we call cardiovascular events. Both arise from similar underlying conditions, such as atherosclerosis —a buildup of fatty deposits in the arteries. According to the American Heart Association, the risk factors for heart attacks and strokes are largely the same: high blood pressure, high cholesterol, smoking, obesity, physical inactivity and diabetes. Therefore, addressing these risk factors can simultaneously reduce the risk of both conditions. Here are ways you can prevent the two: Healthy diet More fruit and veg: The DASH, which emphasises fruit, vegetables, whole grains and lean proteins, has been shown to reduce blood pressure and improve heart health. Less fats: Too much saturated and trans fats can raise cholesterol levels and increase the risk of atherosclerosis. Go for healthier fats like those found in olive oil, nuts, and avocados. Limit salt: High salt intake is linked to high blood pressure, a major risk factor for both heart attack and stroke. The NHS recommends no more than 6g of salt per day for adults. Fibre: Foods high in soluble fibre, such as oats and beans, can help lower cholesterol levels. Exercise Walking, running, cycling, swimming - whatever you like, do it! Aerobic exercise can strengthen the heart and improve circulation. The NHS advises at least 150 minutes of moderate-intensity aerobic activity or 75 minutes of vigorous-intensity activity each week. Strength training exercises can help control weight, improve cholesterol levels, and reduce blood pressure. It is recommended twice a week by the NHS. Manage blood pressure Healthy diet and exercise can help keep your blood pressure in check. But it is worth monitoring it yourself after the age of 40, at least, when the NHS invites adults for a check-up every five years. High blood pressure often has no symptoms but significantly increases the risk of heart attack and stroke. Quit smoking One of the best ways to quit smoking is to use resources provided by NHS Smokefree. Support groups, medications, and other tools to help quit smoking such as vapes could be what you need to kick the habit for good - and it's free. Limit booze Excessive alcohol consumption can increase blood pressure and contribute to weight gain, which can snowball and become a heart health risk. The NHS recommends not regularly drinking more than 14 units of alcohol per week. "Higher risks of cardiovascular diseases were observed for men, and older individuals," researchers added. "We observed stronger relationships of night light with risks of heart failure and coronary artery disease in women." Younger participants were also found at an increased risk for heart failure and atrial fibrillation. The study team suggested that "avoiding light at night may be a useful strategy for reducing risks of cardiovascular diseases". Several other studies have explored the link between sleep and heart disease. Here are three other habits that could be upping your risk. 1. Not sleeping enough Getting enough sleep is important for your heart and circulatory health. It's recommended that people get between seven and nine hours of kip a night. Regularly snoozing five hours a night or less was linked to peripheral artery disease, where blood vessels in the legs become clogged, in a 2023 study. 2. Irregular routine A study published in the Journal of Epidemiology and Community Health last year found that people who do not keep to regular sleep schedules - meaning they went to sleep or woke at differing times - had a higher risk of stroke and heart attack. This was regardless of whether people are getting enough sleep overall. A recent study also warned that just three nights of bad sleep can increase the risk of a heart attack or stroke - even for "perfectly healthy" people. Lack of shuteye triggers molecular mechanisms linked to a greater risk of heart problems, according to the findings. 3. Taking naps A 2023 study found that napping on a regular basis was linked with high blood pressure, which contributes to stroke and heart attacks. People who 'usually' napped had a 12 per cent higher risk of developing high blood pressure, compared to those who never napped. Their risk of stroke was 24 per cent higher.
Gulf Insider
27-06-2025
- Health
- Gulf Insider
More Fetal Losses Than Expected After Pfizer COVID-19 Vaccination In Israel: Study
A higher-than-expected number of miscarriages and other forms of fetal loss were associated with COVID-19 vaccinations in Israel, a new study has revealed. Researchers found 13 fetal losses—four more than the nine expected—for every 100 pregnant women who received a COVID-19 vaccine during weeks eight to 13 in pregnancy, according to the study, which was published as a preprint on the medRxiv server. Most people in Israel, including pregnant women, received the Pfizer-BioNTech COVID-19 vaccine. Pfizer did not respond by publication time to a request for comment. The team behind the study includes Retsef Levi, a Massachusetts Institute of Technology researcher who was recently named to the committee that advises the Centers for Disease Control and Prevention on vaccines, and Dr. Tracy Hoeg, who works for the Food and Drug Administration. The researchers analyzed electronic health records from Maccabi Healthcare Services, one of four organizations that provide health care to Israelis. They looked at 226,395 pregnancies that occurred between March 1, 2016, and Feb. 28, 2022. The primary analysis looked at fetal loss for pregnant women after dose one or dose three of a COVID-19 vaccine, with fetal loss including miscarriage, abortion, and stillbirth. The researchers came up with an expected number of fetal losses based on a model that drew from data before the COVID-19 pandemic, then compared the expected number of fetal losses with those that occurred from week eight of pregnancy onward. They identified 13,214 fetal losses after the COVID-19 pandemic started, compared with 12,846 fetal losses in the reference period, finding that women who received a COVID-19 vaccine during weeks eight to 13 in pregnancy experienced a higher-than-expected number of fetal losses. 'If you believe this result … every 100 women that you would vaccinate during weeks eight to 13, you are going to see close to four additional fetal losses,' Levi told The Epoch Times. The researchers cautioned that more information is required to say for sure that the vaccines cause fetal losses. They also noted that when they carried out the same analysis for pregnant women who received a COVID-19 vaccine during weeks 14 to 27, the number of fetal losses was lower than expected. An additional analysis of pregnant women who received an influenza vaccine from March 1, 2018, to Feb. 28, 2019, also found a lower-than-expected number of fetal losses. The researchers said those results could stem from what is known as healthy vaccine bias—the data could be skewed because people who receive vaccines are typically healthier than those who do not. Maccabi Healthcare Services did not return an inquiry by publication time. Dr. Yaakov Segal, head of obstetrics and gynecology medicine at the organization, is one of the paper's co-authors. Israel's Ministry of Health and the American College of Obstetricians and Gynecologists, which encourages pregnant women to receive a COVID-19 vaccine in any trimester, did not respond to requests for comment by publication time. 'Generally, medical advice to pregnant women follows the precautionary principle and is based on sound and careful research,' Josh Guetzkow, researcher with Hebrew University of Jerusalem and another study co-author, told The Epoch Times via email. 'Our study shows just how irresponsible it was for our health authorities to abandon these core principles.' COVID-19 vaccination was recommended for pregnant women in Israel and the United States early in the COVID-19 pandemic, even though the clinical trials for the vaccines excluded pregnant women. Moderna's clinical trial for pregnant women was ultimately terminated, while Pfizer ended its trial early after enrolling just 175 women. The latter found slightly lower COVID-19 incidence among the vaccinated when compared with those who received a placebo. Some observational studies have determined that pregnant women benefit from COVID-19 vaccination. The Centers for Disease Control and Prevention recently narrowed its COVID-19 vaccine recommendations and no longer advises COVID-19 vaccination during pregnancy. The new paper was published as a preprint, without peer review. Levi said the paper had been rejected by two journals, and the authors decided that the implications were too important to continue to not release it to the public. Guetzkow said the researchers are going to keep trying to get the paper published by a journal.
Time Magazine
08-05-2025
- Health
- Time Magazine
Richard Sever
When Richard Sever co-founded a medical research preprint site—where scientists can share early versions of their research with the public for free—called medRxiv in 2019, he couldn't have foreseen what was coming. By March 2020, the site was getting hundreds of new research paper submissions every week—first from China, then Italy, then the UK and US, mirroring the spread of COVID-19 cases around the world. Sever and his team were working 14-hour days, 7 days a week to screen each paper to verify the science, catch plagiarism, protect patient privacy, and eliminate misinformation. In those days, medRxiv and bioRxiv, a biology research preprint server Sever co-founded in 2013, hosted 25% of all COVID-19 research. To date, bioRxiv and medRxiv have published more preprints than any other biology server. 'We saw these bizarre scenarios where a paper would come out about a new variant of COVID on bioRxiv and medRxiv and you knew how important it was in real time,' says Sever. Had that paper appeared in a journal several months later after peer review, he noted, the findings would no longer have been relevant. One trial that found dexamethasone effective for treating severe COVID went on medRxiv for many weeks before it was in a journal. 'The day it went up, you could see the data, people could read it, physicians around the world could put that into practice,' Sever says. The chaos during COVID-19 proved the importance of sites like medRxiv and bioRxiv in communicating research in an increasingly digital world, and challenged a decades-old publishing and peer review process to modernize. In 2024, the two preprint platforms, which had been embedded within the infrastructure of the well-respected Cold Spring Harbor Laboratory since their inception, announced that they would be breaking out to stand on their own, overseen by an independent non-profit organization, openRxiv. Sever serves as openRxiv's chief science and strategy officer, and works to make the platform an accessible and open place for researchers of all backgrounds to share good science.
Yahoo
24-04-2025
- Business
- Yahoo
Gameto Announces First U.S. Clinical Site Open for Enrollment in Fertilo Study
- Reproductive Fertility Center in Corona, CA to offer novel investigational platform for fertility treatment AUSTIN, Texas, April 24, 2025--(BUSINESS WIRE)--Gameto, a clinical-stage biotech company developing iPSC-based therapies to transform fertility care, today announced that the Reproductive Fertility Center in Corona, CA, led by Dr. Daniel Williams, is now open for patient enrollment in Gameto's first clinical study of Fertilo in the United States. Fertilo is an investigational platform designed to reduce the burden of ovarian stimulation for women undergoing fertility treatment. By using engineered ovarian support cells to promote egg maturation outside of the body, Fertilo aims to shorten or eliminate the need for weeks of hormone injections typically required in conventional in vitro fertilization (IVF) cycles. The trial at Reproductive Fertility Center represents a significant milestone as Gameto expands Fertilo's clinical development across leading fertility centers in the U.S. In addition to this center in California, Gameto expects to open over a dozen additional clinical sites in the coming weeks as part of its U.S. Fertilo study rollout. New sites are anticipated across key states including Florida, Texas, New York, and Connecticut, with more locations to follow. "Opening our first U.S. clinical site for our pivotal study, is an exciting step forward for Gameto and for the future of fertility care," said Dr. Dina Radenkovic, CEO & Co-Founder, Gameto. "We are proud to partner with Dr. Williams and his outstanding team at Reproductive Fertility Center to offer women a new investigational option aimed at making fertility treatment faster, easier, and less invasive." The Fertilo study will evaluate the ability of engineered ovarian support cells to mature patient eggs ex vivo, with the goal of achieving fertilization and embryo development after a much shorter period of ovarian stimulation. Patients participating in the study will receive personalized monitoring and care at Reproductive Fertility Center, one of Southern California's leading fertility clinics. "We are excited to be the first clinical site in the U.S. enrolling patients in this innovative study," said Dr. Daniel Williams, Medical Director of Reproductive Fertility Center. "Our mission has always been to provide patients with access to the latest advances in reproductive medicine. Fertilo has the potential to offer a safer, simpler alternative for women who want to preserve their fertility or start a family. And with the expertise of our clinical team, including Dr. James P. Lin and Dr. Susan Nasab, we are proud to contribute to advancing this important research." Gameto recently published a preprint on medRxiv demonstrating that Fertilo can effectively promote egg maturation, leading to a higher number of viable embryos and significantly improved pregnancy success rates. In mini-stimulation (mini-stim) cycles supplemented with Fertilo, patients achieved a 44% pregnancy rate per cycle after the first embryo transfer, more than double the success rate typically observed with conventional in vitro maturation (IVM), which stands at 20%. Patients treated with Fertilo also had more viable embryos available for transfer, further enhancing their chances of conception. The company plans to open additional clinical sites in its pivotal U.S. Phase 3 clinical trial (NCT06858111) of Fertilo, a first-in-class iPSC-derived therapy. Individuals interested in joining the study can learn more at About FertiloFertilo is Gameto's ovarian support cell (OSC) product that matures eggs outside the body using iPSC-derived cells. By mimicking the natural ovarian environment in vitro, Fertilo enables replacement of ~80% of hormone injections and shortens IVF or egg freezing cycles from 10-14 days to just 2-3 days. This approach offers a potentially safer, less invasive alternative to traditional IVF, significantly reducing patient burden and the risk of ovarian hyperstimulation. About GametoGameto is a biotechnology company developing novel solutions for women's health, starting with infertility. Gameto brings together an experienced scientific management team with the vision and passion to develop a product suite to support women throughout their reproductive journeys. Gameto's lead program, Fertilo, aims to make IVF and egg freezing shorter, safer, and more accessible through reduced hormonal injections by maturing eggs outside of the body. Gameto is led by physician-turned-entrepreneur Dina Radenkovic as CEO and serial entrepreneur and founder of one of North America's largest fertility networks Prelude Fertility, Martin Varsavsky, as Chairman. For more information, go to or follow us on Twitter and Instagram @gametogen and on LinkedIn. View source version on Contacts InvestorKylie Jordankylie@ MediaKimberly HaKKH 917-291-5744 Sign in to access your portfolio
